ClinicaliQ Trial Snapshot
- HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) — Active Not Recruiting • Phase III • NCT06634420.
- Gene therapy NTLA-2002 reduced hereditary angioedema attacks more effectively than placebo in a Phase 3 trial.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE. Conditions: Hereditary Angioedema Interventions: NTLA-2002, Normal Saline IV Administration Lead Sponsor: Intellia Therapeutics Planned Enrollment: 80 participants